Sign in

You're signed outSign in or to get full access.

Andreas Wagner

Chief Human Resources Officer at Alignment Healthcare
Executive

About Andreas Wagner

Andreas Wagner, 55, is Chief Human Resources Officer at Alignment Healthcare (ALHC), having joined on January 8, 2024. He previously served as CHRO at Aerojet Rocketdyne and held senior HR roles at TE Connectivity and Bombardier Transportation; he holds a master’s degree in Sport Science from the University of Munich, Germany . In 2024, ALHC delivered 48.3% revenue growth to $2.704B with positive adjusted EBITDA of $1.3M and 58.6% membership growth to ~189,100, metrics that inform executive incentive design around revenue, adjusted gross profit, adjusted EBITDA, membership, and Star Ratings . Company TSR (value of $100 invested on 3/26/2021) ended 2024 at $64.99 versus $49.74 in 2023, providing context for long‑term equity alignment .

Past Roles

OrganizationRoleYearsStrategic impact
Aerojet RocketdyneChief Human Resources Officer2020–2023Led HR for a technology-based engineering and manufacturing company
TE ConnectivityVice President of Human Resources2014–2019Senior HR leadership at electrical/electronics manufacturer
TE ConnectivityDirector of Human Resources2012–2014Global HR leadership roles
Bombardier TransportationDirector of Human Resources2004–2012HR leadership in aviation/aerospace component manufacturing

External Roles

  • Not disclosed for Mr. Wagner in the proxy .

Fixed Compensation

Item2024Notes
Base salary rate$450,000 Initial 2024 rate as CHRO
Target bonus %85% of base salary Under Annual Incentive Plan (AIP)
AIP “earned” amount (subject to holdback/modifier)$519,119 (135% of target) 75% paid Mar-2025; 25% held back to Q4‑2025 pending Star Ratings modifier
Non‑equity incentive actually paid (2025 for 2024 performance)$389,339 Cash paid in March 2025 (75% of “earned”)
Retirement and benefits401(k) match: 100% of deferrals up to 4% of pay; medical/dental/life/LTD; limited perqs (internet stipend); no defined benefit pension; no nonqualified deferred comp
ClawbackClawback policy consistent with SEC and Nasdaq requirements
Tax gross‑upsNone, other than certain relocation expenses

Performance Compensation

2024 Annual Incentive Plan (AIP) – Metrics, Weights, Results, and Payout

MetricWeightThresholdTargetMaximumActual resultPayout factor
Health plan membership (as of Jan 1, 2025)30%178,250186,000201,500Above target; funded at 200% of target 200%
Adjusted gross profit35%$282.4M$292.4M–$297.4M$312.0MBetween target and max; funded at 133% 133%
Adjusted EBITDA35%($10.0M)$0.0M–$5.0M$20.0MAt target; funded at 100% 100%
Corporate weighted outcome141.7%
Individual modifier (Wagner)WeightResult
Individual/departmental goals25% of AIP (non‑CEO NEOs) 115% (Wagner)
Total “earned” payoutPercent of targetDollar amount
Wagner AIP earned (before holdback)135.0% $519,119
AIP payout schedule75% paid Mar‑2025; 25% paid/forfeited in Q4‑2025 per Star Ratings (3.5≤ no; 4.0=flat; 4.5/5.0=+35%)

Long‑Term Equity – 2024 Awards and Design

GrantGrant dateInstrumentTarget/unitsGrant date fair valueVesting
Sign‑on equity2/7/2024RSU155,763$1,000,00025% on each of 2/7/2025, 2026, 2027, 2028
Annual equity3/13/2024RSU60,000$300,00025% on each of 3/13/2025, 2026, 2027, 2028
Annual equity3/13/2024PSU60,000 target$300,000Earned on fiscal 2026 Revenue and Adjusted EBITDA; vest on/around 2/28/2027, 0–200% of target
  • PSU performance metrics: Revenue and Adjusted EBITDA, measured over FY2026; payout 0–200% of target shares; performance targets not numerically disclosed in the proxy .

Equity Ownership & Alignment

ItemDetail
Beneficial ownership (as of 4/7/2025)35,846 shares; shares outstanding 197,681,510 (beneficial ownership table)
Unvested outstanding awards at 12/31/2024RSUs: 155,763 (sign‑on) + 60,000 (annual); PSUs: 60,000 target; aggregate grant‑date schedules per above
Market value of unvested awards (12/31/2024 at $11.25)RSU 155,763: $1,752,334; RSU 60,000: $675,000; PSU 60,000 (at target): $675,000
Upcoming vesting cadence (supply overhang)~38,941 RSUs vest each 2/7/2025–2028 (sign‑on); ~15,000 RSUs vest each 3/13/2025–2028 (annual); PSUs cliff vesting expected ~2/28/2027 subject to FY2026 performance
Ownership guidelinesExecutives: 2x base salary within 5 years; all NEOs were in compliance as of 12/31/2024
Hedging/pledgingAnti‑pledging policy; short‑sales and options prohibited; limited, pre‑cleared long‑term hedges permitted

Implication: Regular February and March RSU vests create predictable, periodic Form 4 activity (often with sell‑to‑cover tax withholding), which can introduce short‑term technical selling pressure near those dates .

Employment Terms

TopicTerm
Start date / roleJanuary 8, 2024; Chief Human Resources Officer
Agreement termInitial 1‑year term, auto‑renews for 1‑year periods unless non‑renewal notice 90 days prior
AIP targetsTarget bonus 85% of base salary (non‑CEO NEO standard)
Restrictive covenantsNon‑compete during employment; non‑solicit of employees/customers during employment and 1 year post‑termination; perpetual confidentiality and non‑disparagement
Severance (qualifying termination; no CIC)Cash = 1x (base salary + target bonus) = $888,000; prorated AIP for year of termination; up to 12 months COBRA premium share = $23,577; totals per proxy example $1,319,577
Change‑in‑control (CIC) treatmentRSUs/options generally double‑trigger (CIC + qualifying termination) accelerate; PSUs deemed earned at least at target on CIC based on performance through CIC (Board may set at max), with vest contingent on service or accelerate on qualifying termination post‑CIC
CIC + qualifying termination example (Wagner)Cash $888,000; AIP $408,000; equity acceleration valued $3,102,334; COBRA $23,577; total $4,421,911 (12/31/2024 price assumption)
ClawbackApplies to cash incentives and equity upon restatement; SEC/Nasdaq‑compliant

Compensation Structure Analysis

  • Mix and risk: Variable pay dominates via AIP and LTI; 2024 shift to three‑year PSUs (revenue and adjusted EBITDA) increases long‑term performance alignment and reduces short‑term risk‑taking versus prior one‑year PSU design .
  • AIP quality modifier: 25% AIP holdback tied to CMS Star Ratings (−25% to +35%), directly linking cash bonuses to quality outcomes and plan ratings .
  • Governance: Anti‑hedging/pledging, ownership guidelines, and clawback are in place; no options below FMV; no tax gross‑ups other than certain relocation .
  • Peer benchmarking: Committee seeks market‑median positioning; uses independent consultant (FW Cook engaged May 2024) and updated healthcare services peer set for 2025 .
  • Say‑on‑pay: 2024 support at ~86.7%, indicating improved shareholder acceptance of the program .

Investment Implications

  • Alignment and retention: Multi‑year RSU/PSU stack (sign‑on plus annual) with staggered 2/7 and 3/13 vests and a FY2026 PSU performance bridge creates tangible retention hooks and long‑term alignment; anti‑pledging/ownership rules reinforce “skin in the game” .
  • Performance linkage: Cash and equity incentives are tied to membership growth, adjusted gross profit, adjusted EBITDA, and revenue—metrics that management improved in 2024 (48.3% revenue growth; positive adjusted EBITDA), with a quality overlay via Star Ratings .
  • Event risk economics: In a CIC+termination, Wagner’s cash severance equals 1x salary+bonus with full RSU acceleration and PSUs deemed earned at least at target (Board discretion up to max), yielding $4.42M illustrative value at 12/31/2024 prices—an incentive to remain constructive in strategic alternatives while avoiding single‑trigger windfalls on RSUs/options .
  • Technical flow: Predictable sell‑to‑cover around February and March vest dates could create near‑term supply pockets; monitor Form 4s and blackout windows near 2/7 and 3/13 each year .
  • Governance quality: Strong policy stack (clawback, anti‑pledging, ownership, independent consultant) and improved say‑on‑pay support (86.7%) lower governance risk; limited perquisites and no routine tax gross‑ups are shareholder‑friendly .